Answers are grounded in this paper and cite their sources.
Findings reveal the role of peroxidasin in promoting malignant progression in glioblastoma, suggesting a novel therapeutic target.
PXDN is identified as a potential diagnostic indicator for GBM, and PXDN promotes malignant progression in GBM by modulating LDHA. Anti-PXDN therapy may represent a viable new approach to combat GBM.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: